Kenza Health Hub logoGet Started
1 May 2026Injectable drugsSource update: February 2024

Haloperidol Injectable: Dosing and Precautions

Injectable haloperidol guidance for delirium, acute alcohol intoxication, and agitation in psychosis, with strong safety monitoring.

Also searched as

Haloperidol
Prescription under medical supervision

Source reviewed

February 2024

Guide category

Injectable drugs

Safety boundary

Prescription medicine information for clinician-guided use.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Antipsychotic.

Indications

  • Acute confusional state (delirium) and acute alcohol intoxication.
  • Agitation or aggressive behaviour in patients with acute or chronic psychosis, in combination with promethazine.

Forms and strengths, route of administration

  • 5 mg in 1 ml ampoule, 5 mg/ml, for IM injection.

Dose and duration

Change to oral treatment as soon as possible. Reduce the dose by half in older patients, maximum 5 mg daily.

Acute confusional state (delirium) and acute alcohol intoxication

  • Adult: 0.5 to 1 mg, to be repeated after 30 to 60 minutes if necessary. If needed, administer additional doses every 4 hours, maximum 5 mg, for 7 days maximum.

Agitation or aggressive behaviour in patients with acute or chronic psychosis, with promethazine

  • Adult: 5 mg, to be repeated after 30 minutes if necessary.

Contra-indications, adverse effects, precautions

Due to the numerous and potentially severe adverse effects of haloperidol, patients should be kept under close surveillance.

  • Do not administer to patients with cardiac disorders, dementia, Parkinson's disease, or history of neuroleptic malignant syndrome.
  • Administer with caution and carefully monitor use in older patients and patients with hypokalaemia, hypotension, hyperthyroidism, renal or hepatic impairment, or history of seizures.
  • May cause drowsiness, extrapyramidal syndrome, dyskinesia, anticholinergic effects, sexual dysfunction, QT prolongation, ventricular arrhythmia, orthostatic hypotension, and rarely neuroleptic malignant syndrome.
  • Avoid or monitor combination with central nervous system depressants, fluoxetine, paroxetine, sertraline, ritonavir, carbamazepine, rifampicin, phenobarbital, phenytoin, antihypertensive drugs, and drugs that prolong the QT interval.
  • Keep the patient in the supine position for 30 minutes after injection because of the risk of orthostatic hypotension.
  • Pregnancy: re-evaluate whether treatment is still necessary; if continued, administer at the lowest effective dose and observe the neonate if exposed in the third trimester.
  • Breast-feeding: if absolutely necessary, do not exceed 10 mg daily.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.